Icosavax (NASDAQ: ICVX)
Icosavax Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Icosavax Company Info
Icosavax, Inc. engages in the development and commercialization of vaccines against infectious diseases. It focuses on developing vaccine candidates for viral causes of pneumonia in older adults. The company was founded by Neil King and David Baker on November 1, 2017 and is headquartered in Seattle, WA.
News & Analysis
Featured Article
Why Shares of Icosavax Jumped on Tuesday
The company announced positive trial news for its pan-virus vaccine.
Jim Halley | May 23, 2023
Featured Article
Why Icosavax Stock Is Soaring Today
The company's Q4 update made investors feel a little better after receiving disappointing news last week.
Keith Speights | Mar 31, 2022
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.